
NASDAQHealthcareMedical - Specialties
Latest quote
$0.631
+$0.0173 · +2.82%
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Previous close
$0.631
+$0.0173 · +2.82%
Regular session · ET · Market data may be delayed.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Day range
Current $0.631
52-week range
Current $0.631
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
57
Fair Value
Sentiment
53
Mixed
Risk
71
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Day range
Current $0.631
52-week range
Current $0.631
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 85.33M USD | 174.43M USD | 106.34M USD | 97.95M USD | 130.58M USD |
| Cost of goods sold | 42.79M USD | 90.17M USD | 55.89M USD | 60.9M USD | 61.21M USD |
| Gross profit | 42.54M USD | 84.26M USD | 50.45M USD | 37.05M USD | 69.37M USD |
| Research and development | 25.99M USD | 62.41M USD | 25.95M USD | 37.38M USD | 37.94M USD |
| Selling, general, and administrative | 109.86M USD | 156.61M USD | 87.54M USD | 102.29M USD | 98.89M USD |
| Operating expenses | 135.85M USD | 259.5M USD | 127.05M USD | 153.26M USD | 136.83M USD |
| Interest income | 9.18M USD | 20.2M USD | 5.57M USD | 2.23M USD | — |
| Interest expense | 26K USD | 3.32M USD | 4.57M USD | 4.33M USD | 3.82M USD |
| Depreciation and amortization | 10.98M USD | 16.86M USD | 15.18M USD | 15.03M USD | 15.57M USD |
| Operating income | −93.31M USD | −175.24M USD | −76.6M USD | −116.21M USD | −67.46M USD |
| Net income | −74.9M USD | −138.89M USD | −74.66M USD | −190.1M USD | −59.24M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.25
415.06% upsidePrice history unavailable
High $3.25Average $3.25Low $3.25Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.17M0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF2.15M0.00%30.2B USD0.05%$211.44-3.21%
iShares Biotechnology ETFIBB1.83M0.02%10.53B USD0.44%$199.54-2.05%
Schwab U.S. Small-Cap ETFSCHA886.3K0.00%20.45B USD0.03%$30.51-2.83%
Vanguard Health Care ETFVHT418.69K0.00%20.8B USD0.09%$326.69-0.40%
Global X - Genomics & Biotechnology ETFGNOM401.2K0.39%115M USD0.50%$57.08-2.58%
iShares Core S&P Total U.S. Stock Market ETFITOT215.64K0.00%88.06B USD0.03%$150.71-3.52%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
Schwab U.S. Small-Cap ETFSCHA
Vanguard Health Care ETFVHT
Global X - Genomics & Biotechnology ETFGNOM
iShares Core S&P Total U.S. Stock Market ETFITOTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.